Papers - YAMAMOTO Hayato
-
Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
Ozaki K, Hatakeyama S, Narita S, Hata K, Yanagisawa T, Tanaka T, Togashi K, Hamaya T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Kimura T, Habuchi T, Ohyama C.
World J Urol. 2023.1
-
Oncological and functional outcomes of female reproductive organ-sparing radical cystectomy and ileal neobladder construction
Miura H, Hatakeyama S, Tanaka T, Fujita N, Horiguchi H, Tanaka R, Noro D, Tokui N, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.
Urol Oncol 2022.12
-
Relationships of low-grade systemic inflammation and nutritional status with erectile dysfunction severity in men on dialysis
Fujita N, Hatakeyama S, Momota M, Hamaya T, Tobisawa Y, Yoneyama T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.
Andrology 2022.11
-
Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma
2022.10
-
Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer
Fujita N, Hatakeyama S, Momota M, Tobisawa Y, Yoneyama T, Yamamoto H, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.
Sci Rep . 2022.8
-
Association between Aortic Calcification Burden and the Severity of Erectile Dysfunction in Men Undergoing Dialysis: A Cross-Sectional Study
Fujita N, Hatakeyama S, Momota M, Tobisawa Y, Yoneyama T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.
World J Mens Health . 2022.4
-
Renal metastasis of ovarian granulosa cell tumor
Kyo Togashi, Tohru Yoneyama, Mihoko Sutoh Yoneyama, Hayato Yamamoto, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Masayuki Futagami, Chikara Ohyama
IJU Case Rep 2022.3
-
Comparison of neoadjuvant chemohormonal therapy vs. extended pelvic lymph-node dissection in high-risk prostate cancer treated with robot-assisted radical prostatectomy.
Oishi T, Hatakeyama S, Tabata R, Fujimori D, Fukuda M, Shinozaki T, Ishii N, Iwamura H, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Sato S, Ohyama C.
Sci Rep. 2022.3
-
Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study.
Sasaki D, Hatakeyama S, Kawaguchi H, Hatayama Y, Ishibashi Y, Kusaka A, Noro D, Tanaka T, Ito H, Okuyama Y, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Aoki M, Ohyama C.
Urol Oncol 2021.12
-
Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study.
Sasaki D, Hatakeyama S, Kawaguchi H, Hatayama Y, Ishibashi Y, Kusaka A, Noro D, Tanaka T, Ito H, Okuyama Y, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Aoki M, Ohyama C.
Urol Oncol. 2021.12
-
Utility of total cell-free DNA levels for surgical damage evaluation in patients with urological surgeries
Konishi S, Narita T, Hatakeyama S, Yoneyama T, Yoneyama MS, Tobisawa Y, Noro D, Sato T, Togashi K, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.
Sci Rep . 2021.11
-
Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era
Naito S, Kato T, Numakura K, Hatakeyama S, Koguchi T, Kandori S, Kawasaki Y, Adachi H, Kato R, Narita S, Yamamoto H, Ogawa S, Kawamura S, Obara W, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N.
Int J Clin Oncol . 2021.10
-
Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.
Hamaya T, Hatakeyama S, Tanaka T, Kubota Y, Togashi K, Hosogoe S, Fujita N, Kusaka A, Tokui N, Okamoto T, Yamamoto H, Yoneyama T, Yoneyama T, Hashimoto Y, Ohyama C.
BJU Int. 2021.10
-
Oncologic and patient-reported outcomes after robot-assisted radical prostatectomy in men aged ≥75 years
Togashi K, Hatakeyama S, Okamoto T, Kojima Y, Iwamura H, Fujita N, Narita T, Hamano I, Hamaya T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.
Urol Oncol. 2021.10
-
Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer
Kubota Y, Hatakeyama S, Yoneyama T, Yoneyama MS, Hamano I, Konishi S, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.
World J Urol . 2021.9
-
Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era.
Naito S, Kato T, Numakura K, Hatakeyama S, Koguchi T, Kandori S, Kawasaki Y, Adachi H, Kato R, Narita S, Yamamoto H, Ogawa S, Kawamura S, Obara W, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N
International journal of clinical oncology 2021.6
-
Prognostic significance of the Ki67 index and programmed death-ligand 1 expression after radical cystectomy in patients with muscle-invasive bladder cancer
Hirotaka Horiguchi, Ohyama Chikara
Urologic oncology 2021.4
-
Narrative review of urinary glycan biomarkers in prostate cancer
Shingo Hatakeyama , Tohru Yoneyama , Yuki Tobisawa, Hayato Yamamoto, Chikara Ohyama
Transl Androl Urol 2021.4
-
The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma
Okita K, Hatakeyama S, Hagiwara K, Suzuki Y, Tanaka T, Noro D, Tokui N, Fujita N, Konishi S, Okamoto T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.
Urol Oncol 2021.4
-
Prognostic significance of the Ki67 index and programmed death-ligand 1 expression after radical cystectomy in patients with muscle-invasive bladder cancer.
Horiguchi H, Hatakeyama S, Yoneyama T, Yoneyama MS, Tanaka T, Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Yoshizawa T, Hashimoto Y, Kawaguchi T, Ohyama C
Urologic oncology 39 ( 4 ) 238.e9 - 238.e17 2021.4